Ocugen: A Speculative Buy In Biotech Growing Clinical Trials To Billion-Dollar Revenues [Seeking Alpha]
Ocugen, Inc. (OCGN)
Company Research
Source: Seeking Alpha
Their OCU400 program, targeting inherited eye diseases, is progressing to phase 3 clinical trials in 2024. The company's participation in a $5 billion NIAID-funded trial for an inhaled COVID-19 vaccine enhances its financial and strategic position. Funding concerns loom with a cash runway of under a year, necessitating further capital infusion to continue R&D. Despite risks, Ocugen's promising pipeline, particularly OCU400, positions it as a speculative "buy" with substantial upside. Ocugen Inc. ( NASDAQ: OCGN ) is a clinical-stage biotechnology company based in Malvern, Pennsylvania. It is focused on gene and cell therapies and inhalable vaccine development. The OCU400 program, with indications for RP, adRP, and LCA, is progressing to phase 3 clinical trials in 1H 2024. NeoCart, a cell therapy for knee repair, has also advanced to phase 3 trials. Finally, OCGN's participation in the $5 billion NIAID-funded trial for OCU500 inhaled COVID-19 vaccine enhances the company's fina
Show less
Read more
Impact Snapshot
Event Time:
OCGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCGN alerts
High impacting Ocugen, Inc. news events
Weekly update
A roundup of the hottest topics
OCGN
News
- ROSEN, THE FIRST FILING FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGNPR Newswire
- Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards? [Yahoo! Finance]Yahoo! Finance
- DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the FirmAccesswire
- SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Ocugen, Inc. - OCGNAccesswire
- OCGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ocugen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!GlobeNewswire
OCGN
Earnings
- 11/9/23 - Beat
OCGN
Sec Filings
- 4/18/24 - Form S-3
- 4/18/24 - Form S-8
- 4/17/24 - Form 4
- OCGN's page on the SEC website